A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-25

Study Completion Date

2023-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called efavirenz.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

NCT04459598

Healthy Subjects Drug-drug Interaction Pharmacokinetics +1 more

COMPLETED PHASE1

Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment

NCT00162097

HIV Infections Hepatic Impairment

COMPLETED PHASE1

A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects

NCT05560360

B-cell Tumors

COMPLETED PHASE1

Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

NCT00960570

Healthy

COMPLETED PHASE1

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

NCT02164812

HIV/AIDS

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Period 1: Nemtabrutinib

Participants receive a single dose of nemtabrutinib followed by a protocol specified wash-out period.

Group Type EXPERIMENTAL

Nemtabrutinib

Intervention Type DRUG

Oral administration

Period 2: Nemtabrutinib + Efavirenz

Participants receive oral doses of efavirenz once daily on Days 1 to 24 with a single oral dose of nemtabrutinib given with efavirenz on Day 11.

Group Type EXPERIMENTAL

Nemtabrutinib

Intervention Type DRUG

Oral administration

Efavirenz

Intervention Type DRUG

Oral administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nemtabrutinib

Oral administration

Intervention Type DRUG

Efavirenz

Oral administration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK-1026 ARQ 531

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is in good health based on medical history, physical examination, vital sign (VS) measurements, electrocardiograms (ECGs) and laboratory safety tests performed before allocation
* Has a body mass index (BMI) \> 18 kg/m2 and ≤ 32 kg/m\^2

Exclusion Criteria

* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
* Has a history of cancer (malignancy)

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes